Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

INTRODUCTION: Omacetaxine mepesuccinate (omacetaxine) is a first-in-class cephalotaxine that has demonstrated efficacy in CML. In this analysis we evaluated omacetaxine in CML patients with resistance or intolerance to 2 or more tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: Data were pool...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Cortes, Jorge E., Nicolini, Franck E., Wetzler, Meir, Lipton, Jeffrey H., Akard, Luke, Craig, Adam, Nanda, Nisha, Benichou, Annie-Claude, Leonoudakis, Janis, Khoury, H. Jean, Hochhaus, Andreas, Baccarani, Michele, Kantarjian, Hagop M.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3775895/
https://ncbi.nlm.nih.gov/pubmed/23787123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.03.020
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares